Q3 2026 Financial Results
Showing 283 search results
Grifols presents new AMBAR® data from a real-world observational study in patients with Alzheimer’s disease
Grifols increases revenue by 8.4% to EUR 2,040 million and grows net profit by 28% to EUR 162m in Q3’26
Half of Spaniards are unaware that plasma can be donated separately from blood
Grifols strengthens evidence supporting the AMBAR® program in Alzheimer’s disease with real-world evidence data
Grifols signs renewable energy purchase agreement with ENGIE to cover more than half of its electricity consumption in Spain
Grifols announces Last Patient Last Visit in SPARTA, its Phase 3 Outcomes Study of Prolastin®-C in patients with emphysema due to alpha-1 antitrypsin deficiency
Publications
Links to our latest financial and sustainability reports and other recent publications.
Media Contacts
If you're a journalist or media professional with a question, contact our media relations team.